Compare Stocks: TCRX, GANX, RNTX, and IBIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GANX Gain Therapeutics	$1.64 +1.5%	$1.82	$1.53 ▼ $4.34	$71.58M	0.19	456,866 shs	327,561 shs
IBIO iBio	$0.87 -5.3%	$1.29	$0.78 ▼ $3.82	$56.01M	1.26	752,227 shs	1.64 million shs
RNTX Rein Therapeutics	$0.79 +3.2%	$0.79	$0.69 ▼ $2.18	$68.50M	1.35	367,084 shs	307,535 shs
TCRX TScan Therapeutics	$0.24 +4.3%	$0.52	$0.22 ▼ $2.57	$16.13M	1.15	770,817 shs	869,279 shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GANX Gain Therapeutics	0.00%	-4.09%	-4.09%	-8.89%	-20.77%
IBIO iBio	0.00%	-22.58%	-28.90%	-42.32%	+87,099,900.00%
RNTX Rein Therapeutics	0.00%	-0.84%	+1.68%	-18.98%	-42.88%
TCRX TScan Therapeutics	0.00%	-25.74%	-25.13%	-78.17%	-87.98%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GANX Gain Therapeutics	$1.64 +1.5%	$1.82	$1.53 ▼ $4.34	$71.58M	0.19	456,866 shs	327,561 shs
IBIO iBio	$0.87 -5.3%	$1.29	$0.78 ▼ $3.82	$56.01M	1.26	752,227 shs	1.64 million shs
RNTX Rein Therapeutics	$0.79 +3.2%	$0.79	$0.69 ▼ $2.18	$68.50M	1.35	367,084 shs	307,535 shs
TCRX TScan Therapeutics	$0.24 +4.3%	$0.52	$0.22 ▼ $2.57	$16.13M	1.15	770,817 shs	869,279 shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GANX Gain Therapeutics	0.00%	-4.09%	-4.09%	-8.89%	-20.77%
IBIO iBio	0.00%	-22.58%	-28.90%	-42.32%	+87,099,900.00%
RNTX Rein Therapeutics	0.00%	-0.84%	+1.68%	-18.98%	-42.88%
TCRX TScan Therapeutics	0.00%	-25.74%	-25.13%	-78.17%	-87.98%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GANX Gain Therapeutics	2.60	Moderate Buy	$7.67	367.48% Upside
IBIO iBio	3.11	Buy	$5.29	506.86% Upside
RNTX Rein Therapeutics	2.25	Hold	$6.00	655.67% Upside
TCRX TScan Therapeutics	2.13	Hold	$2.67	1,020.45% Upside

Current Analyst Ratings Breakdown

Latest TCRX, GANX, RNTX, and IBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/5/2026	GANX Gain Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
10/5/2026	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
9/21/2026	IBIO iBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/17/2026	IBIO iBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
9/17/2026	IBIO iBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
9/8/2026	TCRX TScan Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/8/2026	TCRX TScan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$1.00
9/4/2026	GANX Gain Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/2/2026	TCRX TScan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$1.00
9/2/2026	TCRX TScan Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/31/2026	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00

(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GANX Gain Therapeutics	$50K	1,431.39	N/A	N/A	$0.48 per share	3.42
IBIO iBio	$100K	560.14	N/A	N/A	$1.54 per share	0.57
RNTX Rein Therapeutics	N/A	N/A	$0.06 per share	13.89	($1.07) per share	N/A
TCRX TScan Therapeutics	$10.32M	1.56	N/A	N/A	$2.16 per share	0.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GANX Gain Therapeutics	-$20.16M	-$0.50	N/A	N/A	N/A	N/A	-161.59%	-118.36%	11/11/2026 (Estimated)
IBIO iBio	-$33.04M	-$0.34	N/A	N/A	N/A	N/A	-40.66%	-35.78%	11/11/2026 (Estimated)
RNTX Rein Therapeutics	-$49.87M	-$1.72	N/A	N/A	N/A	N/A	N/A	-63.69%	N/A
TCRX TScan Therapeutics	-$129.77M	-$0.91	N/A	N/A	N/A	-1,655.35%	-108.72%	-54.47%	11/11/2026 (Estimated)

Latest TCRX, GANX, RNTX, and IBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/28/2026	Q4 2026	IBIO iBio	-$0.0655	-$0.04	+$0.0255	-$0.07	$0.08 million	N/A
8/14/2026	Q2 2026	RNTX Rein Therapeutics	-$0.27	-$0.10	+$0.17	-$0.10	N/A	N/A
8/12/2026	Q2 2026	TCRX TScan Therapeutics	-$0.2534	-$0.23	+$0.0234	-$0.23	$1.88 million	$1.05 million
8/11/2026	Q2 2026	GANX Gain Therapeutics	-$0.1380	-$0.11	+$0.0280	-$0.11	$0.03 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GANX Gain Therapeutics	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GANX Gain Therapeutics	0.02	4.36	4.36
IBIO iBio	N/A	7.85	7.85
RNTX Rein Therapeutics	N/A	4.27	4.27
TCRX TScan Therapeutics	0.31	3.37	3.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GANX Gain Therapeutics	11.97%
IBIO iBio	7.90%
RNTX Rein Therapeutics	90.89%
TCRX TScan Therapeutics	82.83%

Insider Ownership

Company	Insider Ownership
GANX Gain Therapeutics	4.15%
IBIO iBio	1.55%
RNTX Rein Therapeutics	1.50%
TCRX TScan Therapeutics	6.25%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GANX Gain Therapeutics	21	43.64 million	41.83 million	Optionable
IBIO iBio	23	64.31 million	63.31 million	N/A
RNTX Rein Therapeutics	10	86.27 million	84.97 million	N/A
TCRX TScan Therapeutics	142	67.78 million	63.54 million	Not Optionable

TCRX, GANX, RNTX, and IBIO Headlines

Recent News About These Companies

TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock Has Consensus Price Target of $2.67

October 2, 2026 | americanbankingnews.com

TScan Therapeutics (NASDAQ:TCRX) Stock Jumps 1% - Here's What Happened

October 2, 2026 | americanbankingnews.com

Korro Bio (NASDAQ:KRRO) & TScan Therapeutics (NASDAQ:TCRX) Financial Review

October 1, 2026 | americanbankingnews.com

TScan Therapeutics consensus price target decreased by 55.56% to $2.72

September 16, 2026 | msn.com

Wedbush downgrades TScan Therapeutics (TCRX) to neutral from outperform

September 3, 2026 | msn.com

TScan Therapeutics Reorganizes To Focus On Solid Tumor Program; To Cut 75% Jobs; Stock Tumbles 11%

September 2, 2026 | rttnews.com

TScan Therapeutics cuts workforce by 75% and shifts focus to solid tumor program

September 2, 2026 | msn.com

TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction

September 2, 2026 | benzinga.com

TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors

September 2, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Immix Biopharma (IMMX), TScan Therapeutics (TCRX) and enGene Holdings (ENGN)

August 13, 2026 | theglobeandmail.com

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates

August 12, 2026 | zacks.com

TScan Therapeutics Reports First Patient Dosed in Phase 3 ALLOHA-2 Study and Second-Quarter 2026 Results

August 12, 2026 | quiverquant.comQ

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026 | globenewswire.com

TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies

July 29, 2026 | globenewswire.com

TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

June 24, 2026 | globenewswire.com

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic ...

June 23, 2026 | markets.businessinsider.com

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

June 22, 2026 | globenewswire.com

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

June 3, 2026 | businesswire.com

TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss

June 2, 2026 | insidermonkey.com

TScan Therapeutics Expands Authorized Shares After Stockholder Vote

May 22, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRX, GANX, RNTX, and IBIO Company Descriptions

Gain Therapeutics NASDAQ:GANX

$1.64 +0.03 (+1.55%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.66 +0.02 (+1.22%)

As of 10/9/2026 07:58 PM Eastern

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

iBio NASDAQ:IBIO

$0.87 -0.05 (-5.33%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.88 +0.01 (+1.26%)

As of 10/9/2026 07:48 PM Eastern

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

Rein Therapeutics NASDAQ:RNTX

$0.79 +0.02 (+3.21%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.80 +0.00 (+0.13%)

As of 10/9/2026 05:30 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

TScan Therapeutics NASDAQ:TCRX

$0.24 +0.01 (+4.29%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.23 0.00 (-1.68%)

As of 10/9/2026 07:30 PM Eastern

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TCRX, GANX, RNTX, and IBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TCRX, GANX, RNTX, and IBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TCRX, GANX, RNTX, and IBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRX, GANX, RNTX, and IBIO Company Descriptions

Gain Therapeutics NASDAQ:GANX

iBio NASDAQ:IBIO

Rein Therapeutics NASDAQ:RNTX

TScan Therapeutics NASDAQ:TCRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TCRX, GANX, RNTX, and IBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TCRX, GANX, RNTX, and IBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TCRX, GANX, RNTX, and IBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRX, GANX, RNTX, and IBIO Company Descriptions

Gain Therapeutics NASDAQ:GANX

iBio NASDAQ:IBIO

Rein Therapeutics NASDAQ:RNTX

TScan Therapeutics NASDAQ:TCRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools